Douglas H. Thamm

11.2k total citations · 2 hit papers
197 papers, 7.7k citations indexed

About

Douglas H. Thamm is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Small Animals. According to data from OpenAlex, Douglas H. Thamm has authored 197 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Pulmonary and Respiratory Medicine, 70 papers in Genetics and 52 papers in Small Animals. Recurrent topics in Douglas H. Thamm's work include Veterinary Oncology Research (129 papers), Virus-based gene therapy research (69 papers) and Infectious Diseases and Mycology (46 papers). Douglas H. Thamm is often cited by papers focused on Veterinary Oncology Research (129 papers), Virus-based gene therapy research (69 papers) and Infectious Diseases and Mycology (46 papers). Douglas H. Thamm collaborates with scholars based in United States, China and United Kingdom. Douglas H. Thamm's co-authors include David M. Vail, Daniel L. Gustafson, Cheryl A. London, Erik Verner, Joseph J. Buggy, Richard A. Miller, David Loury, Betty Chang, Mint Sirisawad and Lee Honigberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Douglas H. Thamm

187 papers receiving 7.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2010 1.2k citations Douglas H. Thamm et al. profile →
Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document

2013 342 citations Douglas H. Thamm, David M. Vail et al. Veterinary and Comparative Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas H. Thamm United States	46	3.7k	1.8k	1.7k	1.6k	1.3k	197	7.7k
Cheryl A. London United States	50	4.4k 1.2×	1.9k 1.1×	1.8k 1.1×	2.1k 1.3×	1.3k 1.0×	167	7.9k
David M. Vail United States	52	5.9k 1.6×	1.2k 0.7×	2.5k 1.5×	2.5k 1.5×	1.2k 0.9×	177	8.2k
Chand Khanna United States	49	2.8k 0.8×	3.4k 1.9×	1.3k 0.8×	365 0.2×	2.3k 1.8×	126	7.8k
Gary L. Clayman United States	67	1.6k 0.4×	5.0k 2.8×	1.6k 1.0×	105 0.1×	5.7k 4.3×	232	13.8k
Timothy M. Fan United States	37	1.2k 0.3×	1.6k 0.9×	457 0.3×	310 0.2×	968 0.7×	170	4.7k
Ingegerd Hellström United States	72	1.7k 0.5×	5.6k 3.2×	1.7k 1.0×	207 0.1×	5.3k 4.0×	293	18.0k
Richard D. Carvajal United States	54	1.9k 0.5×	4.8k 2.7×	337 0.2×	163 0.1×	7.2k 5.5×	289	12.3k
Karl Erik Hellström United States	51	1.2k 0.3×	3.1k 1.7×	1.1k 0.6×	139 0.1×	3.8k 2.9×	172	11.8k
David Y. Mason United Kingdom	63	1.3k 0.3×	3.4k 1.9×	638 0.4×	116 0.1×	2.6k 2.0×	183	12.7k
Andrew Davies United Kingdom	54	628 0.2×	2.2k 1.3×	551 0.3×	137 0.1×	2.8k 2.2×	310	10.7k

Countries citing papers authored by Douglas H. Thamm

Since Specialization

Citations

This map shows the geographic impact of Douglas H. Thamm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas H. Thamm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas H. Thamm more than expected).

Fields of papers citing papers by Douglas H. Thamm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas H. Thamm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas H. Thamm. The network helps show where Douglas H. Thamm may publish in the future.

Co-authorship network of co-authors of Douglas H. Thamm

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas H. Thamm. A scholar is included among the top collaborators of Douglas H. Thamm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas H. Thamm. Douglas H. Thamm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klawitter, Jost, Alexander Karpeisky, Douglas H. Thamm, et al.. (2025). Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs. Molecules. 30(2). 354–354.

Thamm, Douglas H.. (2024). Novel Treatments for Lymphoma. Veterinary Clinics of North America Small Animal Practice. 54(3). 477–490. 1 indexed citations

Waldron, Cherry-Ann, et al.. (2024). High specificity and sensitivity of spot urine normetanephrine-to-creatinine ratios in the diagnosis of canine pheochromocytoma. Journal of the American Veterinary Medical Association. 263(3). 359–367.

Burton, Jenna H., et al.. (2024). Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine. 38(4). 2282–2292. 1 indexed citations

Martin, Tiffany, et al.. (2023). Configuration of pathologic fractures in dogs with osteosarcoma following stereotactic body radiation therapy: A retrospective analysis. Veterinary and Comparative Oncology. 21(1). 131–137. 5 indexed citations

Huebner, Shane M., Dawn M. Albrecht, Kristina A. Matkowskyj, et al.. (2021). Tumor aggressiveness is independent of radiation quality in murine hepatocellular carcinoma and mammary tumor models. International Journal of Radiation Biology. 97(8). 1140–1151. 2 indexed citations

Regan, Daniel P., Lyndah Chow, Sunetra Das, et al.. (2021). Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Clinical Cancer Research. 28(4). 662–676. 50 indexed citations

Thamm, Douglas H., et al.. (2020). Biological behaviour of primary osteosarcoma of the digits, metacarpal and metatarsal bones in dogs. Veterinary and Comparative Oncology. 19(4). 735–742. 2 indexed citations

Meleo, Karri A., Gerald Post, Craig A. Clifford, et al.. (2020). Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal of Veterinary Internal Medicine. 34(2). 882–889. 8 indexed citations

10.

Burton, Jenna H., et al.. (2014). Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma. Journal of Veterinary Internal Medicine. 28(5). 1569–1574. 24 indexed citations

11.

Thamm, Douglas H., et al.. (2013). DNA Repair Deficiency as a Susceptibility Marker for Spontaneous Lymphoma in Golden Retriever Dogs: A Case-Control Study. PLoS ONE. 8(7). e69192–e69192. 15 indexed citations

12.

Ehrhart, E. J., et al.. (2011). Expression and Function of Survivin in Canine Osteosarcoma. Cancer Research. 72(1). 249–259. 39 indexed citations

13.

Vail, David M., Douglas H. Thamm, Jeffrey N. Bryan, et al.. (2011). Biological activity of toceranib (Palladia) in canine anal gland anal SAC adenocarcinoma (AGASACA). Veterinary and Comparative Oncology. 9(1). 1 indexed citations

14.

Sottnik, Joseph L., Sheetal Rao, Mary H. Lafferty, et al.. (2010). Association of Blood Monocyte and Lymphocyte Count and Disease-Free Interval in Dogs with Osteosarcoma. Journal of Veterinary Internal Medicine. 24(6). 1439–1444. 56 indexed citations

15.

Paoloni, Melissa, Anita Tandle, Christina Mazcko, et al.. (2009). Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature. PLoS ONE. 4(3). e4972–e4972. 88 indexed citations

16.

Lawrence, Jessica, Lisa J. Forrest, William M. Adams, David M. Vail, & Douglas H. Thamm. (2008). Four-Fraction Radiation Therapy for Macroscopic Soft Tissue Sarcomas in 16 Dogs. Journal of the American Animal Hospital Association. 44(3). 100–108. 21 indexed citations

17.

Thamm, Douglas H., Maura G. O’Brien, & David M. Vail. (2008). Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. Veterinary and Comparative Oncology. 6(2). 126–132. 27 indexed citations

18.

Thamm, Douglas H. & David M. Vail. (2007). Aftershocks of Cancer Chemotherapy: Managing Adverse Effects. Journal of the American Animal Hospital Association. 43(1). 1–7. 14 indexed citations

19.

Thamm, Douglas H., et al.. (2003). In vitro effects of 2‐methoxyestradiol on canine tumour cells. Veterinary and Comparative Oncology. 1(3). 159–167. 2 indexed citations

20.

Thamm, Douglas H. & David M. Vail. (1998). Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. American Journal of Veterinary Research. 59(3). 286–289. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact